No improvement in patient outcomes seen in hospitals with pay-for-performance programs

 

With pay-for-performance expanding across US under Affordable Care Act, policymakers should focus on creating incentive program that works

 

Boston, MA (March 28, 2012) – Paying hospitals to improve their quality of care, known as pay-for-performance, has gained wide acceptance in the U.S. and Medicare has spent tens of millions of dollars on bonuses and rewards for hospitals to improve. However, little is known about whether pay-for-performance actually improves patient outcomes over the long term. A new study from Harvard School of Public Health (HSPH) finds no evidence that the largest hospital-based P4P program in the U.S. improved 30-day mortality rates, a measure of whether patients survive their hospitalization.

 

Given that the Affordable Care Act calls for the Centers for Medicare and Medicaid Services (CMS) to expand pay-for-performance to nearly all hospitals in 2012, the findings call into question whether this payment approach will have a beneficial effect on patient care.

 

The study appears online March 28, 2012 in the New England Journal of Medicine.

 

"These results suggest that the way we have currently conceived of pay-for-performance is unlikely to have any meaningful impact on patient outcomes," said Ashish Jha, associate professor of health policy and management at HSPH and lead author of the study.

 

The researchers, including senior author Arnold Epstein, professor and chair of the Department of Health Policy and Management at HSPH, analyzed data provided by 252 hospitals participating in Medicare’s Premier Hospital Quality Incentive Demonstration program. They examined 30-day mortality rates for more than 6 million patients with acute myocardial infarction, congestive heart failure, pneumonia, or coronary artery bypass graft surgery between 2004 and 2009. Non-Premier hospitals—those not part of Medicare’s pay-for-performance program—were used as a control group.

 

The results showed that there was no impact on patient outcomes for hospitals in the Premier pay-for-performance program compared with non-Premier hospitals. In addition, no difference was found in outcomes even for conditions in which mortality rates were explicitly incentivized—acute myocardial infarction and coronary bypass graft surgery. Even among poor-performing hospitals, which have the most to gain by improving quality of care, improvements were comparable to poor-performing non-Premier hospitals.

 

"Our findings suggest that both the size of the incentives and the targets matter. In the Premier demonstration, the incentives were small and patient outcomes were not the major focus. It is not surprising, in retrospect, that this program failed to improve patient care," said Epstein.

 

"We need to better align financial incentives with delivery of high quality care," said Jha. "This study suggests that in order to improve patient care, we are going to have to work a lot harder to identify and implement an incentive program that works."

 

 

The study was funded by the Robert Wood Johnson Foundation.

 

  • "The Long-Term Effect of Premier Pay for Performance on Patient Outcomes," Ashish K. Jha, Karen E. Joynt, E. John Orav, Arnold M. Epstein, New England Journal of Medicine, 10.1056, online March 28, 2012

 

Harvard School of Public Health is dedicated to advancing the public’s health through learning, discovery and communication. More than 400 faculty members are engaged in teaching and training the 1,000-plus student body in a broad spectrum of disciplines crucial to the health and well being of individuals and populations around the world. Programs and projects range from the molecular biology of AIDS vaccines to the epidemiology of cancer; from risk analysis to violence prevention; from maternal and children’s health to quality of care measurement; from health care management to international health and human rights. For more information on the school visit www.hsph.harvard.edu

 

 


 

Harvard School of Public Health, 28.03.2012 (tB).

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…